重庆招聘

岗位职责Job Responsibility：
1.负责BD团队的培训；
2.协助BD团队与制药企业进行科学方面的沟通；
3.和制药企业biomarker团队对接，参与临床试验的咨询和方案修订；
4.临床项目医生端的沟通；
5.组织和参与具体药企业务项目的内部沟通及会议；
6.和生信、研发等团队沟通业务模式；
7.药企合作业务相关科学资料制作，培训，外部宣讲等工作
任职资格:
1.国内外知名学府毕业，专业不限，博士以上学历；
2.具有医学或分子生物相关专业知识背景；
3.具有肿瘤学教育背景或从业经验优先；
4.有企业客户商业开发经验，或者有与药企进行诊断或临床研究等合作方面的项目管理经验优先；
5.具有国际药企，或诊断企业，或CRO的职业背景优先；
6.具有团队管理经验优先；
7.良好的中英文沟通能力。

关于燃石医学
燃石医学（纳斯达克代码：BNR）成立于2014年，公司使命为“用科学守护生命之光”，专注于为肿瘤精准医疗提供具有临床价值的二代基因测序（NGS）。公司业务及研发方向主要覆盖：1）基于NGS的肿瘤患病人群检测，6年间，燃石累计检测样本超过18.5万例，在中国市场份额领跑行业；2）基于NGS的癌症早检，目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局（NMPA）颁发的中国肿瘤NGS检测试剂盒，在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核，以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品，推动肿瘤精准医疗领域的发展。

About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.